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The complete eradication of solid tumours by chemotherapy
agents is often compromised by the presence of treatment-resistant
hypoxic cells within a tumour (Kennedy, 1987). Several bioreduc-
tive drugs have been developed to overcome this problem. These
agents are prodrugs which undergo metabolic reduction in hypoxic
cells and, therefore, specifically target this subpopulation
(Workman and Stratford, 1993). Combination of bioreductive
drugs with radiation has shown a beneficial interaction, e.g.
tirapazamine (TPZ: 3-amino-1,2,4-benzotriazine-1,4-dioxide) and
RB6145 (a[(2-bromoethyl)amino-2-hydroxypropyl}-2-nitro-
imidazole) have both been shown to enhance the anti-tumour
effect of X-rays (Brown and Lemmon, 1990; Adams et al, 1992).
More recently bioreductive drugs have been combined with cancer
chemotherapy agents. Tirapazamine has been shown to potentiate
the anti-tumour effect of a range of chemotherapy drugs including
cyclophosphamide and cisplatin (Langmuir et al, 1994; Siemann,
1996; Dorie and Brown, 1997). RB6145 has been shown to
enhance the anti-tumour effect of lomustine and cyclophos-
phamide (Siemann, 1994).
AQ4N (1,4-Bis{[dimethylamino-N-oxide)ethyl]amino}5,8-
dihydroxy-anthracene-9,10-dione) is a novel bioreductive drug
which is metabolized in hypoxic conditions to AQ4, a cytotoxic
metabolite which binds with high affinity to DNA and is a potent
inhibitor of DNA topoisomerase II (Patterson, 1993; Smith et al,
1996). Previous studies have shown that AQ4N can significantly
enhance the anti-tumour effect of both single and fractionated
doses of radiation (McKeown et al, 1995, 1996).
This paper aims to assess the ability of AQ4N to enhance the
anti-tumour effect of cyclophosphamide in three murine tumour
models and to compare this to the efficacy of tirapazamine as a
potentiator of cyclophosphamide. In addition, the toxic effect of
AQ4N and tirapazamine on normal bone marrow will be assessed
using a spleen colony assay.
MATERIALS AND METHODS
Tumour models
The T50/80 tumour is a poorly differentiated mammary carcinoma
which arose in a female B6D2F1 mouse (Moore et al, 1988).
Tumours were implanted intradermally (i.d.) on the rear dorsum of
male BDF mice aged 8–12 weeks using early passages (4–12) of
the tumour. Male C3H mice aged 8–12 weeks were implanted i.d.
with SCCVII or RIF-1 tumour cells. Each mouse received 2 ´ 105
tumour cells in 0.05 ml phosphate-buffered saline (PBS). Tumour
stocks of SCCVII and RIF-1 cells were maintained by the protocol
of Twentyman et al (1980). All animal experiments were carried
out in accordance with the UK Animals (Scientific Procedures)
Act 1986.
Drug preparation and administration
AQ4N (15 mg ml–1) and cyclophosphamide (5 mg ml–1) were
made up in distilled water. Tirapazamine (3 mg ml–1) was prepared
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1469in PBS and due to its low solubility it was dissolved by sonicating
for 20 min (McAleer et al, 1992). All drugs were administered as a
single intraperitoneal (i.p.) injection. Systemic toxicity was
monitored by measuring animal weight three times weekly.
Cyclophosphamide was administered as a single i.p. injection
(0–250 mg kg–1) in order to obtain a dose–response curve. For
combined treatments AQ4N (50–150 mg kg–1) or tirapazamine
(25 mg kg–1 or 50 mg kg–1) were administered 30 min prior to a
single i.p. injection of cyclophosphamide (50–100 mg kg–1). In
some experiments this time interval was increased to 6 h or 24 h
for AQ4N and 150 min or 24 h for tirapazamine (see Results for
details).
Measurement of tumour response to treatment:
tumour growth delay
BDF mice were treated when the tumour reached 6.5–7.5 mm
GMD (geometric mean of three orthogonal diameters). Tumours
were measured three times weekly and the time taken to reach
double its treatment volume (VDT) was used as a measure of anti-
tumour efficacy. Tumour growth delay (TGD) was calculated by
subtracting the mean VDT for control tumours from that obtained
after drug exposure. The effect on tumour growth was assessed
using the analysis of variance test (ANOVA).
Measurement of tumour response to treatment:
in vivo–in vitro clonogenic assay
C3H mice bearing SCCVII and RIF-1 tumours were treated with
drug combinations when the tumours reached a volume of
100–200 mm3. After 24 h the tumours were excised, minced and
digested with an enzyme cocktail (6 mg DNAase, 2 mg collage-
nase and 2 mg pronase per 10 ml PBS) to produce a single cell
suspension. The cells were counted, diluted as necessary, plated
and incubated at 37°C in 95% air/5% carbon dioxide for 12–14
days. Colonies were fixed and stained with 0.4% crystal violet in
methanol and then scored by eye. Surviving fraction (SF) was
calculated as the number of colonies counted divided by the
number of cells plated for a given treatment, divided by the same
fraction determined for untreated control tumours.
Normal tissue toxicity
The response of a normal tissue to AQ4N and tirapazamine in
combination with cyclophosphamide was evaluated in the bone
marrow of BDF mice by the spleen colony assay (Till and
McCullough, 1961). Donor mice were injected i.p. with various
doses and combinations of the drugs (see Results for details).
Twenty-four hours later, bone marrow cells were isolated from the
femurs of donor mice by flushing through PBS (0.7 ml ´ 2). Bone
marrow cells from six mice were pooled, counted and injected into
the tail vein of six recipient BDF mice, which had been whole
body irradiated with 9 Gy 24h previously. The spleens were
removed from the recipient mice 8 days later, and immersed in
Bouin’s stain for 1.5 h prior to fixation in formalin. Spleen
colonies were counted by eye and surviving fraction was calcu-
lated as before. Statistical significance was determined by the
Student’s  t-test.
RESULTS
The anti-tumour effect of drug combinations: T50/80
tumour model
AQ4N showed only a minimal inhibition of tumour growth at all
doses (Figure 1). When AQ4N was administered 30 min prior to
cyclophosphamide (100 mg kg–1), T50/80 tumour growth delay
ranged from 14.2 days (50 mg kg–1 of AQ4N) to 16.7 days
(150 mg kg–1 of AQ4N), (Figure 1). A similar effect was observed
when the time interval between administration of the two drugs
was increased to 6 h. Statistical analysis showed that combining
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Figure 1 Interaction of the bioreductive drugs AQ4N and tirapazamine
(TPZ) with cyclophosphamide (CPM) in the T50/80 tumour model. AQ4N
(50–150 mg kg–1) was administered as a single i.p. injection 30 min or 6 h
prior to cyclophosphamide (100 mg kg–1). Tirapazamine (25 mg kg–1) was
administered as a single i.p. injection 30 min prior to cyclophosphamide
(100 mg kg–1). Results were obtained from six to nine tumours per treatment
group. Values are means ± s.e.
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Figure 2 Dose–response curve for cyclophosphamide (CPM). BDF mice
bearing the T50/80 tumour were treated with a single i.p. dose of
cyclophosphamide (100–250 mg kg–1). Results were obtained from six to
nine tumours per treatment group. Values represent mean ± s.e.AQ4N (50–150 mg kg–1) with cyclophosphamide resulted in a
significant increase in anti-tumour effect compared with
cyclophosphamide alone (P = 0.0001). There was no significant
difference between results obtained using the 30 min or 6 h treat-
ment intervals (P = 0.15). In both cases, the anti-tumour effect of
AQ4N (100 mg kg–1) in combination with cyclophosphamide (100
mg kg–1) was found to be approximately equivalent to a single 200
mg kg–1 dose of cyclophosphamide (TGD = 14.9) (Figure 2).
Tirapazamine (25 mg kg–1) alone had only a limited effect on
tumour growth. When tirapazamine (25 mg kg–1) was combined
with cyclophosphamide (100 mg kg–1), the TGD was calculated as
10.8 days (Figure 1). This was significantly better than the anti-
tumour effect seen with cyclophosphamide alone (P = 0.0013) and
was approximately equivalent to the effect of a 150 mg kg–1 dose
of cyclophosphamide alone (Figure 2).
The anti-tumour effect of drug combinations: SCCVII
tumour model
The anti-tumour effect of AQ4N or tirapazamine in combination
with cyclophosphamide was evaluated in the SCCVII tumour
using an in vivo–in vitro clonogenic assay. Cyclophosphamide
gave almost 3 logs of cell kill at the higher dose tested (100 mg
kg–1). Combination of tirapazamine (50 mg kg–1) administered
30 min before cyclophosphamide at each dose caused an increase
in tumour cell kill of about 1 log (Figure 3). AQ4N (100 mg kg–1)
administered either 30 min, 6 h or 24 h prior to cyclophosphamide
at each dose resulted in an increased cell kill of at least 3 logs
(Figure 3; Table 1). Changing the schedule with AQ4N showed no
appreciable difference in the anti-tumour effect with the maximal
cell kill obtained even if the interval between cyclophosphamide
and AQ4N administration was 24 h (Table 1).
The anti-tumour effect of drug combinations: RIF-1
tumour model
The effect of AQ4N in combination with cyclophosphamide was
also investigated in the RIF-1 model. The results are similar to
those observed in the SCCVII model, with AQ4N enhancing the
anti-tumour effect of cyclophosphamide by greater than 3 logs of
cell kill (Figure 4). This is an underestimation of the anti-tumour
effect as no colonies were detected with 106 cells. Again the time
scheduling of AQ4N made no difference to the overall anti-tumour
effect observed (Table 1). Tirapazamine (50 mg kg–1) caused only
a slight increase in anti-tumour effect when administered 24 h
prior to cyclophosphamide (100 mg kg–1) (Figure 4).
Normal tissue toxicity: spleen colony assay
AQ4N was found to be less toxic than tirapazamine towards
bone marrow cells. AQ4N alone, even at the highest dose, i.e.
Anti-tumour effect of cyclophosphamide 1471
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Figure 3 Interaction of the bioreductive drugs AQ4N and tirapazamine
(TPZ) with cyclophosphamide (CPM) in the SCCVII tumour model. AQ4N
(100 mg kg–1) and tirapazamine (50 mg kg–1) were administered as a single
i.p. injection 30 min prior to CPM (100 mg kg–1). Tumours were excised 24 h
after treatment and clonogenic cell survival measured. Six to nine tumours
were treated in each group
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Figure 4 Interaction of the bioreductive drugs AQ4N and tirapazamine
(TPZ) with cyclophosphamide (CPM) in the RIF-1 tumour model. AQ4N
(100 mg kg–1) or TPZ (50 mg kg–1) was administered as a single i.p. injection
30 min prior to CPM (100 mg kg–1). Tumours were excised 24 h after
treatment and clonogenic cell survival measured. Six to nine tumours were
treated in each group
Table 1 The anti-tumour effect of AQ4N administered at three different
times prior to cyclophosphamide in the SCCVII and RIF-1 tumours
Surviving fraction (SF)
Treatment Rif-1 SCCVII
CPM (100 mg kg–1) 3.43 ´ 10–4 8.80 ´ 10–4
AQ4N 30 min prior to CPM < 1.0 ´ 10–6 < 1.0 ´ 10–6
AQ4N 6 h prior to CPM < 1.0 ´ 10–6 < 1.0 ´ 10–6
AQ4N 24 h prior to CPM < 1.0 ´ 10–6 < 1.0 ´ 10–6
Each of the drugs was administered i.p. as a single dose. AQ4N (100 mg kg-1)
was administered 30 min, 6 h and 24 h prior to cyclophosphamide
(100 mg kg-1). The anti-tumour effect was assessed by the clonogenic assay
and the surviving fraction calculated. Results were obtained from 6–9
tumours per treatment group.200 mg kg–1, caused no significant toxicity compared with
untreated bone marrow cells (Figure 5). Cyclophosphamide
proved to be more myelotoxic than either of the bioreductive
agents causing a maximum cell kill of 1 log. The administration of
AQ4N (100 mg kg–1) or tirapazamine (25 mg kg–1) 30 min prior to
cyclophosphamide (100 mg kg–1) resulted in some enhancement in
bone marrow toxicity compared to cyclophosphamide (100 mg
kg–1) alone (P = 0.001) (Figure 6). The effect of tirapazamine
administered 24 h prior to cyclophosphamide also resulted in a
significant (P = 0.0005) enhancement of bone marrow toxicity.
However, increasing the time interval for administration to 6 h
between AQ4N and cyclophosphamide reduced bone marrow
toxicity, compared to the effect observed at the 30 min time
interval. In fact, the administration of AQ4N 6 h prior to
cyclophosphamide did not significantly potentiate cyclophos-
phamide toxicity (P = 0.895) (Figure 6).
DISCUSSION
AQ4N has previously been shown to enhance the anti-tumour
effect of both single and fractionated irradiation in the T50/80
tumour model (McKeown et al, 1995, 1996). The aim of this study
was to determine if a similar enhancement could be achieved with
the chemotherapy drug cyclophosphamide in the T50/80, SCCVII
and RIF-1 tumour models systems. Tirapazamine was compared
to AQ4N, since tirapazamine is the most successful bioreductive
drug to enter clinical trials (Johnson et al, 1997).
In the T50/80 study a significant increase in the anti-tumour
effect of AQ4N was observed when it was combined with a single
dose of cyclophosphamide (100 mg kg–1). The effect was found to
occur at AQ4N doses as low as 50 mg kg–1 (P = 0.0001) and was
independent of scheduling over a 6-h period (Figure 1). The
anti-tumour effect of AQ4N combined with cyclophosphamide
(100 mg kg–1) was equivalent to that produced by a single
200 mg kg–1 dose of cyclophosphamide alone (Figure 2), i.e. a
50% reduction in cyclophosphamide dose.
The additive effect of these two agents may result from a
mechanism similar to that proposed for AQ4N and radiation.
The cyclophosphamide will preferentially target cells that are
oxygenated since it is a prodrug requiring cytochrome P450 mixed
function oxidase activation. Upon activation, the resulting mustard
is likely to alkylate DNA and other macromolecules in the close
vicinity. In addition, cells closer to blood vessels will be preferen-
tially exposed to higher doses and are more likely to be killed.
AQ4N does not bind to DNA and will, therefore, diffuse through
the tumour cell population until it enters a hypoxic cell, it will then
become metabolized and the reduction product, AQ4, will bind to
DNA (Patterson et al, 1993; McKeown et al, 1996; Smith et al,
1996). A possible explanation of the additive effect is that the drug
combinations kill two distinct cell populations. A similar effect
was observed with radiation where an increase in anti-tumour
effect was reported when AQ4N was administered between 4 days
before and 6 h after a single 12 Gy dose of radiation (McKeown
et al, 1995).
When cyclophosphamide (100 mg kg–1) was used in combina-
tion with tirapazamine it was necessary to reduce the tirapazamine
dose to 50% of its maximum tolerated dose (i.e. 25 mg kg–1)
because of unacceptable weight loss observed with higher dose
combinations. A significant increase in anti-tumour effect was
observed with this combination (Figure 1), which was equivalent
to a single 150 mg kg–1 dose of cyclophosphamide alone
(Figure 2). This result correlated well with three earlier studies
combining tirapazamine and cyclophosphamide (Holden et al,
1992; Langmuir et al, 1994; Siemann et al, 1996). In all three
studies, tirapazamine was found to enhance the anti-tumour effect
of a single dose of cyclophosphamide and in two of the three
1472 OP Friery et al
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Figure 5 The effect of AQ4N, tirapazamine (TPZ) and cyclophosphamide
(CPM) on bone marrow toxicity. BDF mice were dosed i.p. with a range
of doses: AQ4N (50–200 mg kg–1), TPZ (12.5–50 mg kg–1) and CPM
(50–200 mg kg–1). Survival of bone marrow cells was assessed by the
spleen colony assay. To allow drug doses to be plotted on the same scale,
they are plotted with the highest dose designated as HD. Results are the
means ± s.e for six mice
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Figure 6 The effect of AQ4N and tirapazamine (TPZ) on the bone marrow
toxicity of cyclophosphamide (CPM). BDF mice were dosed i.p. with AQ4N
(100 mg kg–1) 30 min and 6 h prior to CPM (100 mg kg–1). TPZ (25 mg kg–1)
was administered 30 min and 24 h prior to CPM (100 mg kg–1). The survival
of bone marrow cells was assessed by the spleen colony assay. Results are
means ± s.e. for six micestudies this was accompanied by an increase in systemic toxicity
(Holden et al, 1992; Siemann 1996). Overall, in the T50/80 tumour
model AQ4N was more effective than tirapazamine when
combined with cyclophosphamide.
When drug combinations were examined in the SCCVII model,
a clonogenic assay was used to measure anti-tumour efficacy.
Again both bioreductive drugs enhanced the anti-tumour effect
of cyclophosphamide with AQ4N showing a better anti-tumour
effect than tirapazamine (Figure 3). Our results for tirapazamine,
although not directly comparable, showed a similar level of
enhancement to that reported in the RIF-1 tumour by Dorie and
Brown (1997). A particularly impressive result was observed with
AQ4N since for 6/9 tumours the number of clonogenic cells
remaining after treatment was beyond the limits of detection of the
assay, i.e. less than 1 in 5 ´ 106 cells were capable of forming
colonies.
The results were equally impressive in the RIF-1 tumour model,
again AQ4N increased the effect of cyclophosphamide alone by
greater than 3 logs of cell kill. The time scheduling of AQ4N prior
to cyclophosphamide did not influence the anti-tumour efficacy
of the combination of the two drugs (Table 1). Tirapazamine,
although reported to enhance the anti-tumour affect of cyclo-
phosphamide in the RIF-1 model (Dorie and Brown, 1997), did
not prove to be very successful in this particular study.
In order to assess the therapeutic potential of AQ4N it was neces-
sary to evaluate normal tissue toxicity in a relevant systemic tissue.
The bone marrow was selected since AQ4 is structurally similar to
mitoxantrone; the major limiting toxicity of mitoxantrone is to the
bone marrow. Cyclophosphamide is also myelotoxic and therefore
it might be predicted that mitoxantrone, and possibly AQ4, would
enhance the bone marrow toxicity of cyclophosphamide. In fact
AQ4N significantly enhanced the anti-tumour effect of cyclophos-
phamide without increasing the toxicity of cyclophosphamide
towards bone marrow cells when administered with a 6 h interval.
In contrast, the administration of tirapazamine prior to cyclophos-
phamide resulted in a greater than additive toxicity at the 24 h
interval. This result is in agreement with a previous report in which
the effect of tirapazamine on cyclophosphamide toxicity was inves-
tigated (Siemann et al, 1996). When both drugs were given 30 min
prior to cyclophosphamide there was some additional cell kill
which may be relevant clinically. However, the enhanced toxicity
had resolved by 6 h with AQ4N although it was still detectable with
tirapazamine at the 24-h interval.
In conclusion AQ4N shows very considerable enhancement of
the anti-tumour effect of cyclophosphamide. In comparison we
found a more limited enhancement of the anti-tumour effect
of cyclophosphamide with tirapazamine. However, evidence
suggests that tirapazamine is more effective with cisplatin and it is
currently showing efficacy in this combination in clinical trials
(Johnson et al, 1997). Combination of AQ4N with cyclophos-
phamide shows little dependence on dose over 50–150 mg kg–1
AQ4N and appears maximal for a schedule that includes dosing up
to 24 h apart. If these results can be reproduced in the clinic AQ4N
could provide appreciable enhancement of the anti-tumour
efficacy of cyclophosphamide with no major enhancement of
systemic toxicity.
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